[go: up one dir, main page]

WO2011133668A3 - Methods and compositions for the treatment of cancer - Google Patents

Methods and compositions for the treatment of cancer Download PDF

Info

Publication number
WO2011133668A3
WO2011133668A3 PCT/US2011/033247 US2011033247W WO2011133668A3 WO 2011133668 A3 WO2011133668 A3 WO 2011133668A3 US 2011033247 W US2011033247 W US 2011033247W WO 2011133668 A3 WO2011133668 A3 WO 2011133668A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
genes
methods
biological activity
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/033247
Other languages
French (fr)
Other versions
WO2011133668A2 (en
Inventor
Joan S. Brugge
Taru Muranen
Gordon Mills
Laura Selfors
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Harvard University
University of Texas at Austin
Original Assignee
University of Texas System
Harvard University
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, Harvard University, University of Texas at Austin filed Critical University of Texas System
Publication of WO2011133668A2 publication Critical patent/WO2011133668A2/en
Publication of WO2011133668A3 publication Critical patent/WO2011133668A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Methods for identifying a cancer in a subject by measuring the expression level or biological activity of the following genes or proteins encoded by said genes: mTOR or PI3K and of one or more of IGFIR, B-bcl-2, src, rsk, FAK, VEGF, and PERK in the sample; where a decrease in the expression level or biological activity of mTOR or PI3K, and an increase in the expression level or biological activity of one or more of IGFIR, bcl-2, src, rsk, FAK, VEGF, and PERK identifies a cancer in the subject, as well as pharmaceutical compositions, kits, and methods for treating a subject diagnosed with, or at risk of developing cancer, by administering inhibitors of said genes or proteins encoded by said genes.
PCT/US2011/033247 2010-04-20 2011-04-20 Methods and compositions for the treatment of cancer Ceased WO2011133668A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32611110P 2010-04-20 2010-04-20
US61/326,111 2010-04-20

Publications (2)

Publication Number Publication Date
WO2011133668A2 WO2011133668A2 (en) 2011-10-27
WO2011133668A3 true WO2011133668A3 (en) 2011-12-15

Family

ID=44834784

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/033247 Ceased WO2011133668A2 (en) 2010-04-20 2011-04-20 Methods and compositions for the treatment of cancer

Country Status (1)

Country Link
WO (1) WO2011133668A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102282168A (en) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 Human serum albumin linker and its conjugate
JP2013501808A (en) * 2009-08-12 2013-01-17 ポニアード ファーマシューティカルズ， インコーポレイテッド Method for promoting apoptosis and inhibiting metastasis
CA2803004A1 (en) 2010-06-29 2012-01-12 Poniard Pharmaceuticals, Inc. Oral formulations of kinase inhibitors
MX343894B (en) 2010-06-30 2016-11-28 Poniard Pharmaceuticals Inc * Synthesis and use of kinase inhibitors.
CA2825894C (en) 2011-02-02 2021-11-30 Amgen Inc. Prognosis of cancer using a circulating biomarker
US20140227289A1 (en) * 2011-05-13 2014-08-14 Stephen Michael Cohen Compounds and methods for treating insulin resistance syndrome
JP2014532057A (en) * 2011-09-30 2014-12-04 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド How to treat mucoepidermoid carcinoma
KR20200034818A (en) * 2012-03-15 2020-03-31 시그날 파마소티칼 엘엘씨 Treatment of cancer with tor kinase inhibitors
WO2013188763A1 (en) * 2012-06-15 2013-12-19 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
US20150202287A1 (en) * 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
US9750705B2 (en) 2012-08-31 2017-09-05 The Regents Of The University Of California Agents useful for treating obesity, diabetes and related disorders
US9561245B2 (en) 2012-09-06 2017-02-07 The Board Of Regents Of The University Of Texas System Combination treatments for melanoma
CN103664935A (en) * 2012-09-17 2014-03-26 杨育新 Compounds for treating traumatic brain injury diseases and application thereof
US10172796B2 (en) 2012-12-03 2019-01-08 Manli International Ltd. Use of umirolimus and its derivatives for treating cancer
US10799473B2 (en) 2013-03-04 2020-10-13 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of inhibiting IGF-1R activation or downtream signalling thereof to reduce radiation-induced cellular senescence
US9572828B2 (en) 2013-07-18 2017-02-21 The Board Of Regents Of The University Of Texas System Treatment for melanoma
WO2015054477A1 (en) * 2013-10-09 2015-04-16 The General Hospital Corporation Methods of diagnosing and treating b cell acute lymphoblastic leukemia
CN103784460A (en) * 2014-02-18 2014-05-14 广州金域医学检验中心有限公司 Combined drug for inhibiting lung carcinoma cell migration, pharmaceutical preparation and detection method
CN103908452A (en) * 2014-02-18 2014-07-09 广州金域医学检验中心有限公司 Composite drug and medicinal preparation for inhibiting lung cancer cell metastasis and detection method for lung cancer cell metastasis
WO2016007945A1 (en) * 2014-07-11 2016-01-14 Genesys Research Institute Compositions and methods for treating or preventing cardiac hypertrophy
JP6684780B2 (en) 2014-08-25 2020-04-22 ソーク インスティテュート フォー バイオロジカル スタディーズ Novel ULK1 inhibitors and methods of using same
TW201639573A (en) * 2015-02-03 2016-11-16 吉李德科學股份有限公司 Combination therapies for treating cancers
EP3144014A1 (en) 2015-09-21 2017-03-22 Commissariat A L'energie Atomique Et Aux Energies Alternatives A synthetic lethal drug combination for treating renal cell carcinoma
US20190125735A1 (en) * 2015-12-29 2019-05-02 Board Of Regents, The University Of Texas System Inhibition of p38 mapk for the treatment of cancer
TR201703149A2 (en) * 2017-03-01 2018-09-21 Univ Yeditepe CHEMOTHERAPIC MEDICINE COMPOSITION
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
WO2020058072A1 (en) * 2018-09-18 2020-03-26 Société des Produits Nestlé S.A. Src inhibitor compounds for skeletal muscle modulation, methods and uses thereof
CN110624108B (en) * 2019-01-08 2022-04-05 浙江大学 Application of Fas or ligand FasL thereof as target in preparation of antitumor drugs
WO2020257615A1 (en) * 2019-06-21 2020-12-24 Nidhi Singh Therapeutic compositions and methods for treating cancers
EP4051286A1 (en) * 2019-10-29 2022-09-07 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and compositions for treating uveal melanoma
CN114903999A (en) * 2021-02-10 2022-08-16 上海交通大学医学院附属第九人民医院 Pharmaceutical composition for treating hemangioma and/or vascular malformation and application thereof
CN119199122A (en) * 2024-10-21 2024-12-27 浙江大学 Application of DEPTOR-based biomarkers in the diagnosis and treatment of liver cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109163A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc. Nanoparticle comprising rapamycin and albumin as anticancer agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109163A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc. Nanoparticle comprising rapamycin and albumin as anticancer agent

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CARBONI ET AL.: "BMS-754807, a small molecule inhibitor of isulin-like growth factor IR/IR", MOLECULAR CANCER THERA., vol. 8, 2009, pages 3341 - 3349 *
DEBNATH ET AL.: "Akt Activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner.", JOUMAL OF CELL BIOLOGY, vol. 163, 2003, pages 315 - 326 *
LEE ET AL.: "Adenovirus expressing shRNA to IGF-1 R enhances the chemosensitivity of lung cancer cell lines by blocking IGF-1 pathway.", LUNG CANCER, vol. 55, no. 3, 2007, pages 279 - 86 *
MA ET AL.: "Novel Agents on the Horizon for Cancer Therapy.", CANCER JOUMAL CLINICAL, vol. 59, 2009, pages 111 - 137 *
YUAN ET AL.: "Dual silencing of type 1 insulin-like growth factor and epidermal growth factor receptors to induce apoptosis of nasopharyngeal cancer cells.", J LARYNGOL OTOL., vol. 122, no. 9, 2008, pages 952 - 960 *

Also Published As

Publication number Publication date
WO2011133668A2 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
WO2011133668A3 (en) Methods and compositions for the treatment of cancer
Yong et al. Ribosomal proteins RPS11 and RPS20, two stress-response markers of glioblastoma stem cells, are novel predictors of poor prognosis in glioblastoma patients
WO2012149493A3 (en) Hsp90 combination therapy
WO2014004990A3 (en) Methods for determining drug efficacy using cereblon-associated proteins
HK1200322A1 (en) Immunobinders directed against sclerostin
WO2016196298A8 (en) Therapeutic and diagnostic methods for cancer
WO2010091049A3 (en) Diagnosis and treatment of cancer
MX2011008748A (en) Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs.
BR112012008665A2 (en) cancer treatment
EA201590630A1 (en) METHODS OF TREATMENT AND DIAGNOSTICS ASSOCIATED WITH LYZYLOXIDE-LIKE PROTEIN 2 (LOXL2)
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
EA201291260A1 (en) ANTIBODY AGAINST TROP-2 PERSON HAS ANTI-TUMOR ACTIVITY IN VIVO
HK1199068A1 (en) Identification of gene expression profile as a predictive biomarker for lkb1 status
WO2012109466A3 (en) Long non-coding rna spry4-it1 as a diagnostic and therapeutic agent
WO2012170704A3 (en) Methods and compositions of predicting activity of retinoid x receptor modulator
MX2013003929A (en) Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate.
Chua et al. Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer
WO2011052906A3 (en) Use of eif3m for the diagnosis and treatment of cancer
MX2009001070A (en) Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma.
WO2010116003A3 (en) Method for predicting the response of non-small cell lung cancer patients to targeted pharmacotherapy
WO2012131092A3 (en) Method and kits for the prediction of response/nonresponse to the treatment with an anti-egfr antibody in patients with colorectal cancer of all uicc stages
WO2014023808A3 (en) Method for evaluating a cancer patient for propensity to respond to a therapy
WO2013066944A3 (en) Biomarkers for cancer characterization and treatment
WO2014169011A3 (en) Methods for treating immune diseases
WO2012078648A3 (en) Novel method of cancer diagnosis and prognosis and prediction of response to therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11772633

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11772633

Country of ref document: EP

Kind code of ref document: A2